H1B Report
Side-by-side comparison

CVS Pharmacy Inc. vs Deloitte Consulting LLP

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
CVS Pharmacy Inc.
RIRank #FEIN 05-0340626
Entity B
Deloitte Consulting LLP
PARank #4FEIN 06-1454513

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricCVS Pharmacy Inc.Deloitte Consulting LLP
Total filings2,07980,813
Certified %93.75%98.23%
Denied %0.14%1.09%
Withdrawn %0.63%0.61%
Cert-withdrawn %5.48%0.07%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateRIPA

Outcomes — CVS Pharmacy Inc.

DOL case-status mix.

Outcome breakdown: Certified 93.8%, Cert-withdrawn 5.5%, Withdrawn 0.6%, Denied 0.1%
Outcome breakdown
OutcomeShare
Certified93.8%
Cert-withdrawn5.5%
Withdrawn0.6%
Denied0.1%
Certified93.8%
Cert-withdrawn5.5%
Withdrawn0.6%
Denied0.1%

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

CVS Pharmacy Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20108
FY20110
FY201232
FY2013101
FY2014180
FY2015130
FY2016132
FY2017113
FY201898
FY2019116
FY202032
FY20219
FY20220
FY2023188
FY2024346
FY2025403
FY2026191
Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612

Top 5 occupations — Deloitte Consulting LLP

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.